Sign in

Michael Torok

Director at AMARIN CORP PLC\UKAMARIN CORP PLC\UK
Board

About Michael Torok

Michael Torok, age 46, was appointed as a non-executive, independent director of Amarin on April 4, 2025. He co-founded and serves as Managing Director of JEC Capital Partners, with prior roles as CFO of Integrated Dynamics Engineering and earlier positions at PwC. He holds a B.S. in Accounting & Finance and a Master’s in Finance from Boston College. He is nominated for re‑election at the May 13, 2025 AGM and, as of the proxy date, is considered independent by the Board .

Past Roles

OrganizationRoleTenureCommittees/Impact
JEC Capital Partners, LLCCo‑Founder & Managing Director2008–presentCapital allocation, M&A and operational improvement focus as investor/operator .
Integrated Dynamics Engineering (acq. by Aalberts)Chief Financial Officer2006–2009Led finance through sale to Aalberts Industries (XAMS: AALB) .
PricewaterhouseCoopers LLPVarious rolesEarly careerFinancial services focus .

External Roles

OrganizationRoleTenureNotes
Liberated Syndication, Inc. (Libsyn)DirectorDec 2022–presentPublic company board experience .
Carisma Therapeutics Inc. (NASDAQ: CARM)DirectorMar 2023–Oct 2024Former public company directorship .
Photon Control Inc. (TSX: PHO)Director2016–2018Former public company directorship .
Symbility Solutions Inc.Director2015–2018Former public company directorship .
Various (general)Committee contributionsN/APress release notes contributions across audit, compensation, nominating & governance, strategic and pricing committees at past boards .

Board Governance

  • Independence: The Board determined all directors other than the CEO are independent; this includes Mr. Torok as of the April 10, 2025 proxy .
  • Committee assignments: On appointment (Apr 4, 2025) he had not been assigned to any committees; committee assignments may be set after the AGM .
  • Attendance: The Board held 10 meetings in 2024 and all then‑serving directors met the 75% attendance threshold; Torok was appointed in 2025, so no 2024 attendance record applies to him .
  • Board leadership: Independent Chair (Dr. Odysseas Kostas); key committees are fully independent; independent directors hold sessions at every meeting .
  • Re‑election: Ordinary resolution to re‑elect Michael Torok at the 2025 AGM (Proposal No. 13) .

Fixed Compensation (Director)

ComponentAmount/TermsNotes
Annual Board Retainer (non‑employee director)$62,500Paid quarterly in arrears; proration for partial year .
Non‑Executive Chairman Retainer$95,000Not applicable to Torok unless designated Chair .
Committee Member RetainersAudit: $12,000; Remuneration: $10,000; Nominating & Gov: $5,000In addition to Board retainer; Torok had no assignments at appointment .
Committee Chair RetainersAudit: $25,000; Remuneration: $20,000; Nominating & Gov: $11,000In addition to Board retainer .
Retainer settlement electionCash or unregistered ordinary shares (ADS‑priced or par floor), election window each quarterProvides alignment option; priced at greater of ADS close +10 days or £0.50 par value .

Performance Compensation (Director Equity)

Equity ElementGrant Value/MixVestingOther Terms
Initial grant for new directors (as revised Feb 2024)$262,500 total; 75% options / 25% RSUsOptions: 1/3 at yr 1 then quarterly over next 2 yrs; RSUs: annual over 3 yrsUnder 2020 Plan; CIC: director equity fully vests on change of control .
Ongoing annual grant$175,000 total; 75% options / 25% RSUsOptions: annual over 3 yrs; RSUs: annual over 3 yrsUnder 2020 Plan; CIC: director equity fully vests on change of control .

Structure signals pay‑for‑performance: heavier option weighting (75%) shifts director equity toward stock price outcomes; Amarin reduced director equity sizes and increased option mix in 2023/Jan 2024 to align with market medians .

Other Directorships & Interlocks

CompanySectorRolePotential Interlock/Conflict Relevance
Liberated Syndication, Inc.Podcasting/AdtechDirectorNo disclosed commercial ties to Amarin; governance only .
Carisma Therapeutics Inc.BiotechFormer DirectorNo disclosed ties to Amarin; tenure ended Oct 2024 .
Photon Control Inc.Semi equipmentFormer DirectorNo disclosed ties to Amarin .
Symbility Solutions Inc.InsurtechFormer DirectorNo disclosed ties to Amarin .

The Company reports no related‑party transactions since Jan 1, 2024, and Torok is not party to any Item 404(a) transactions on appointment .

Expertise & Qualifications

  • Capital markets, M&A, capital resources, and operational improvements experience (JEC, CFO background) .
  • Financial oversight and board experience; contribution across core board committees noted in press release .
  • Accounting and finance academic credentials (Boston College) .

Equity Ownership

Holder (direct/indirect)SharesNotes
Michael Torok – direct970,000Directly owned as of Apr 4, 2025 .
JEC II Associates, LLC (managed by Torok)3,000,000Indirect beneficial ownership via manager status .
The MOS Trust (trustee manager entity managed by Torok)880,000Indirect beneficial ownership via trustee manager role .
Total beneficial ownership4,850,000Represents 1.17% of outstanding shares (414,186,296) .
  • Ownership guidelines (directors): 3× annual cash retainer; five years to attain (non‑employee directors elected in 2023 have until 2028) .
  • Hedging/pledging: Prohibited absent Audit Committee approval; Company anti‑hedging/anti‑pledging policy applies to directors .

Governance Assessment

  • Alignment: Material personal/affiliated ownership of ~1.17% aligns incentives with shareholders; option‑heavy director equity mix further ties compensation to share price outcomes .
  • Independence and oversight: Board deems him independent; independent Chair and fully independent key committees support effective oversight, though Torok had no committee assignment at appointment, limiting near‑term committee‑level influence until assignments are made post‑AGM .
  • Engagement/attendance: Board met 10 times in 2024 with all then‑directors meeting attendance thresholds; Torok’s attendance will be assessable in 2025 reporting .
  • Pay structure quality: Director pay offers cash/equity election and market‑median sizing; change‑in‑control full vesting is standard but can be shareholder‑sensitive; the increased option weighting is a positive alignment signal .
  • Conflicts and related‑party risk: Company discloses no related‑party transactions; 8‑K affirms no Item 404(a) transactions for Torok on appointment; hedging/pledging restrictions mitigate alignment risks. Continued monitoring warranted given indirect holdings via entities he manages, although no pledges are disclosed .

RED FLAGS (monitor)

  • No committee assignment at appointment (may be temporary; monitor post‑AGM committee placements) .
  • Change‑in‑control acceleration for director equity (industry standard but can face investor scrutiny) .

Supportive Signals

  • Significant beneficial ownership and option‑heavy director equity structure .
  • Independent status within an independently led board framework .
  • No related‑party transactions disclosed; deed of indemnity to be executed in standard form .

Employment & Contracts (Director)

  • Appointment date: April 4, 2025; service through 2025 AGM; nominated for re‑election .
  • Deed of indemnity: Company expects to enter into standard director deed of indemnity with Torok .

Director Compensation Structure Analysis

Aspect2024–2025 Policy DetailImplication
Cash retainer$62.5k + committee/Chair fees; quarterly; share election availableFlexibility and potential for higher equity alignment via share elections .
Initial equity award$262.5k (75% options/25% RSUs); staggered vestingStrong price alignment; vesting supports retention .
Annual equity award$175k (75% options/25% RSUs)Sustained price alignment over tenure .
CIC treatmentFull vesting of director awardsStandard; monitor investor sentiment on CIC acceleration .

Say‑on‑Pay & Shareholder Feedback (context)

  • 2024 say‑on‑pay approval ~79.5% of votes cast; Board and Remuneration Committee expanded engagement and simplified incentive design, including heavier option weighting and clearer outcomes‑based goals (executive program context) .

Related‑Party Transactions

  • None reported since Jan 1, 2024; Torok specifically not party to any Item 404(a) transactions per his 8‑K appointment disclosure .

Past Roles (detail table)

OrganizationRoleTenureCommittees/Impact
JEC Capital Partners, LLCCo‑Founder & Managing Director2008–presentInvestor/operator; capital markets, M&A, operations .
Integrated Dynamics Engineering (Aalberts Industries)CFO2006–2009Led finance; sale to Aalberts .
PwCVariousN/AFinancial services focus .

External Roles (detail table)

CompanyRoleTenureNotes
Liberated Syndication, Inc.DirectorDec 2022–presentPublic company board .
Carisma Therapeutics Inc.DirectorMar 2023–Oct 2024Former director .
Photon Control Inc.Director2016–2018Former director .
Symbility Solutions Inc.Director2015–2018Former director .
Various (general)Committee contributionsN/AContributions across audit/comp/N&G/strategic/pricing committees (press release) .

Equity Ownership (detail table)

CategoryShares% of OutstandingSource/Notes
Direct970,000As of April 4, 2025 .
Indirect – JEC II Associates, LLC (manager: Torok)3,000,000Indirect via entity managed by Torok .
Indirect – The MOS Trust (trustee manager entity managed by Torok)880,000Indirect via trust arrangement .
Total4,850,0001.17% (of 414,186,296)Beneficial ownership table and footnote; outstanding share count as of Feb 28, 2025 .

Notes on Policies Relevant to Alignment

  • Director stock ownership guideline: 3× annual cash retainer; 5 years to comply (directors from 2023 cohort have until 2028) .
  • Insider trading policy: Prohibits hedging and pledging absent Audit Committee approval; clawback policy in place for executives (governance backdrop) .